About
DiaGyn is developing a wide range of solutions targeting unmet needs in the area of womens health, integrating drug development and molecular genomics with personalized therapeutic approaches. The company is focused on addressing BRCA1/2 mutations in ovarian and breast cancer using a treatment strategy based on nanoparticle technology. DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). The innovative product comprises 100 nm mesoporous silica nanoparticles (MSNP) loaded with the antineoplastic docetaxel and capped with the cyclic oligosaccharide cyclodextrin. The cyclodextrin cap linked to the silica particles prevents the uncontrolled release of chemotherapy from the pores before arrival at the intended site. The special design of DiaGyns nanoparticles involves a sensitive linker that selectively senses the high levels of -galactosidase and low pH encountered in the surrounding EOC cells, releasing the drug into the malignant cells while leaving normal tissues largely unaffected. DiaGyn is a subsidiary of Goldman Hirsh Partners.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is DiaGyn's current operational status?
- DiaGyn is currently inactive, having ceased operations in December 2022.
- What is DiaGyn's primary focus in drug development?
- DiaGyn focuses on developing solutions for women's health, specifically targeting BRCA1/2 mutations in ovarian and breast cancer using nanoparticle technology.
- What is the name of DiaGyn's lead product?
- DiaGyn's lead product is DIG790, developed for the treatment of patients with advanced epithelial ovarian cancer (EOC).
- How does DiaGyn's DIG790 product work?
- DIG790 uses 100 nm mesoporous silica nanoparticles (MSNP) loaded with docetaxel and capped with cyclodextrin. A sensitive linker in the nanoparticles selectively releases the drug into malignant EOC cells by sensing high levels of -galactosidase and low pH.
- When was DiaGyn founded?
- DiaGyn was founded in September 2015.
- What is DiaGyn's relationship with Goldman Hirsh Partners?
- DiaGyn is a subsidiary of Goldman Hirsh Partners.
- How many employees did DiaGyn have?
- DiaGyn had 4 employees.
- Who is a founder of DiaGyn?
- Roy Farfara is a founder of DiaGyn.